Anders Ekblom – Vice Chairman of the Board, LEO Pharma

09.07.2019
Anders Ekblom is the former EVP Global Medicines Development AstraZeneca and CEO of AstraZeneca AB Sweden and is currently the Vice Chairman of the Board of LEO Pharma A/S. Additionally, he also occupies board positions on many biotech companies (Elypta, Alligator Bioscience AB, Mereo Biopharma Group Plc, AnaMar Medical AB). Anders shares his wealth of experience within the pharmaceutical industry and discusses the current healthcare and pharmaceutical climate within Sweden.  
Sweden, although a small country, is able to form global connections amazingly well
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Sweden, Research, AstraZeneca, LEO Pharma, Innovation

Related Interviews

Martina Stenerdal – General Manager, PPD Scandinavia

As a worldwide research powerhouse, Sweden is benefiting from the presence of multinational clinical research organizations like PPD. Martina Stenerdal, general manager for PPD in Scandinavia, discusses the company’s 25-year…

Jan Hellqvist – General Manager, KLIFO Sweden

With almost three decades of experience in the Swedish life science industry, Jan Hellqvist, general manager of KLIFO in Sweden, explains why the country has seen the number of clinical…

Anders Millerhovf – CEO, CTC Clinical Trial Consultants, Sweden

In a fast-changing Nordic CRO industry, CTC Clinical Trial Consultants has opted to differentiate with a unique one-stop-shop approach. CEO Anders Millerhovf reveals how the relatively young company has managed…

Related Articles

Nordics / Danish-Swedish Clinical Trial Collaboration: Better Together?

Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…

Europe / Sustainability & Pharma Procurement: Are You ‘Green’ Enough? 

In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…

Sweden / A Global Testbed for AMR Incentive Models

Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been…

Latest Report

Saudi Arabia Pharma Report 2022

Related Content

Sweden
Research
AstraZeneca
LEO Pharma
Innovation